CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma-Reference-Cited by-同舟云学术

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Published:2016-08-18 Issue:7 Volume:128 Page:959-970
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Nijhof Inger S.¹²,Casneuf Tineke³,van Velzen Jeroen⁴,van Kessel Berris¹,Axel Amy E.⁵,Syed Khaja⁵,Groen Richard W. J.¹,van Duin Mark⁶,Sonneveld Pieter⁶,Minnema Monique C.²,Zweegman Sonja¹,Chiu Christopher⁵,Bloem Andries C.⁴,Mutis Tuna¹,Lokhorst Henk M.¹²,Sasser A. Kate⁵,van de Donk Niels W. C. J.¹

Affiliation:

1. Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;

2. Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;

3. Janssen Research & Development, Beerse, Belgium;

4. Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;

5. Janssen Research & Development, Spring House, PA; and

6. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Abstract

Key Points Response to the CD38-targeting antibody daratumumab is significantly associated with CD38 expression levels on the tumor cells. Resistance to daratumumab is accompanied by increased expression of complement-inhibitory proteins.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/7/959/1398201/959.pdf

Reference57 articles.

1. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.;van de Donk;Expert Opin Pharmacother,2013

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.;Kumar;Leukemia,2012

3. Where we were, where we are, where we are going: progress in multiple myeloma.;Bergsagel;Am Soc Clin Oncol Educ Book,2014

4. Current treatment landscape for relapsed and/or refractory multiple myeloma.;Dimopoulos;Nat Rev Clin Oncol,2015

5. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.;van de Donk;Leukemia,2012

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Fc‐mediated effector functions of monoclonal antibodies: The example of HexaBodies;Immunological Reviews;2024-09-14

2. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11

3. A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide;Antibodies;2024-09-10

4. Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma;Molecular Biology Reports;2024-09-09

5. Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells;Expert Review of Vaccines;2024-09